| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 651 | 1.622 | 6.635 | 13.829 | 18.077 | 27.267 | 61.547 |
| Total Income - EUR | - | - | - | 651 | 1.622 | 6.635 | 13.829 | 18.077 | 27.267 | 61.547 |
| Total Expenses - EUR | - | - | - | 384 | 0 | 201 | 5.234 | 3.189 | 4.987 | 5.056 |
| Gross Profit/Loss - EUR | - | - | - | 267 | 1.622 | 6.434 | 8.595 | 14.888 | 22.280 | 56.491 |
| Net Profit/Loss - EUR | - | - | - | 267 | 1.622 | 6.434 | 8.281 | 14.684 | 20.956 | 47.627 |
| Employees | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Urogine S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 0 | 0 | 0 | 2.865 | 2.410 | 2.402 | 2.902 |
| Current Assets | - | - | - | 506 | 2.118 | 8.467 | 12.692 | 28.017 | 44.602 | 49.507 |
| Inventories | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | 506 | 1.167 | 760 | 0 | 13.573 | 23.131 | 32.730 |
| Cash | - | - | - | 0 | 951 | 7.707 | 12.692 | 14.444 | 21.472 | 16.776 |
| Shareholders Funds | - | - | - | 267 | 1.884 | 8.237 | 15.333 | 30.064 | 46.710 | 46.003 |
| Social Capital | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debts | - | - | - | 239 | 234 | 230 | 225 | 362 | 295 | 6.406 |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Urogine S.r.l.